Power Law company profile

TOT Biopharm

Biotech & Life Sciences · China · Founded 2009 · IPO 2019 Thoroughbred

Oncology CDMO for antibody-drug conjugates and biologics

Valuation

$419M

Market cap · May/2026

Revenue

$151M

Latest reported FY

EBITDA

$14M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

7 investors on TOT Biopharm's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Chengwei Capital

Series B+ 6 investors entered at this stage

Cathay Capital

Center Ventures

China Universal Asset Management

Yuanta Financial Holdings Group

99Fund

GoldTech Capital

Global footprint

Where TOT Biopharm has talent and traffic

Workforce by country

🇨🇳 China HQ

Book a demo for the full country breakdown

Web traffic by country

120 monthly visits
across markets

🇳🇱 Netherlands83.3%

Top 1 markets shown

Market sentiment

What the market is saying about TOT Biopharm

An AI-synthesized read of the highest-engagement posts about TOT Biopharm on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TOT Biopharm on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles